Biogen Inc. (BIIB)

280.19
11.84 4.41
NASDAQ : Health Technology
Prev Close 268.35
Open 294.32
Day Low/High 278.17 / 294.99
52 Wk Low/High 215.78 / 374.99
Volume 3.25M
Avg Volume 1.79M
Exchange NASDAQ
Shares Outstanding 163.19M
Market Cap 44.03B
EPS 31.50
P/E Ratio 8.34
Div & Yield N.A. (N.A)

Biogen downgraded at Citi

Rev's Forum: Don't Be Seduced by the Market's Dark Side

Too many turn bearish too quickly just because they can't find any entry points.

Trader's Daily Notebook: Gusher for Oil Stocks

Trader's Daily Notebook: Gusher for Oil Stocks

Big move for biotechs isn't pleasant.

Closing Bell: Icahn Ups Hertz Stake; S&P 500 Rises as Oil Tops $50

Closing Bell: Icahn Ups Hertz Stake; S&P 500 Rises as Oil Tops $50

The S&P 500 clinched a new closing high for 2016 as crude closed above $50 a barrel on Tuesday.

Here’s Why Shares of Biogen and Alexion Tanked On Tuesday

Here’s Why Shares of Biogen and Alexion Tanked On Tuesday

Shares of Biogen and Alexion Pharmaceuticals took a hit Tuesday after their promising new products failed clinical trials.

Trending Tickers: Z, VRX, BIIB, ALXN

U.S. indices are up as oil continues its climb past $50 a barrel.

Biogen Is Going Down a Rabbit Hole of Mediocrity and Uncertainty

Biogen Is Going Down a Rabbit Hole of Mediocrity and Uncertainty

We've seen yet another disaster in Biogen's history of overpromising and under-delivering.

Midday Report: Biogen Slides on Phase 2 Study Fail; U.S. Stocks Climb

Midday Report: Biogen Slides on Phase 2 Study Fail; U.S. Stocks Climb

Stocks compounded early-week gains, helped along by a less-hawkish Federal Reserve and crude gains.

4 Possible Acquisition Targets in Biotech

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

Biogen Is Looking Quite Strong

Biogen Is Looking Quite Strong

There is a fresh buy signal on the chart.

Cramer: Avoid Sloppiness by Watching Your Stock Table Manners

The essence of sloppiness is to let it all ride, so look at your portfolio and decide what has moved too much and what you should take off.

Intermediate Trade: International Paper

Intermediate Trade: International Paper

I prefer a bullish synthetic call.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Biotech Is Ripe for M&A: Analysts

After an asset price drop, large pharmaceutical companies are looking for strategic purchases.

Biogen Is Ready to Rise After a 10-Month Downward Spiral

Biogen Is Ready to Rise After a 10-Month Downward Spiral

BIIB could be headed above $300 over the intermediate term.

Some Stocks Are Really Cheap

Some Stocks Are Really Cheap

There are lots of winners in the first quarter.

Biogen estimates, target cut at Leerink

5 Facts You Should Know About Biogen

5 Facts You Should Know About Biogen

Biogen is a biotech company focused on treating a host of diseases.

Midday Report: SunEdison Files for Bankruptcy; U.S. Stocks Mixed

Midday Report: SunEdison Files for Bankruptcy; U.S. Stocks Mixed

U.S. stocks were mixed as a slew of earnings report kept investors busy.

U.S. Stocks Slip as Oil Pares Gains; General Motors Posts Upbeat Quarter

U.S. Stocks Slip as Oil Pares Gains; General Motors Posts Upbeat Quarter

U.S. stocks slip as oil prices lose steam in Thursday's trading session

9 Health Names to Like Amid the Rhetoric

9 Health Names to Like Amid the Rhetoric

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

Cramer: See What Happens When Takeover Talk Gets Going?

Cramer: See What Happens When Takeover Talk Gets Going?

With Pfizer deal dead, Allergan is ready to go shopping.

More Proof That a Correction Is Near

More Proof That a Correction Is Near

The lack of fear, by way of the VIX, speaks volumes about where the market is headed.

Jim Cramer Is Bullish on Salesforce.com and Palo Alto Networks

Jim Cramer Is Bullish on Salesforce.com and Palo Alto Networks

TheStreet's Jim Cramer is on the floor of the NYSE talking MLB's Opening Day and answering social media questions.

The S&P Clears an Important Hurdle

The S&P Clears an Important Hurdle

Let's also take a look at Biogen, a biotech I like.

Biogen's Path of Least Resistance Is Up

Biogen's Path of Least Resistance Is Up

The biotech company's shares remain range-bound, but a fresh rally appears to be brewing.

Markers Spotted Point to a Top

Markers Spotted Point to a Top

At the very least, move those stop loss levels in very close on long positions.

Cramer: The Biotech Stocks Are in No Man's Land Right Now

The group rallied yesterday, but it's still not out of the woods.

Challenges Ahead for Biogen

Challenges Ahead for Biogen

The short- and longer-term trends are both bearish here as biotechs struggle.

Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com

Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com

TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.